Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 2/20 | 0.62 |
| ▸ | MC4R | P32245 | 6/20 | 0.53 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.52 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3180726 | 1.00 | RORC (0.62) | RORCMC4RS1PR5S1PR1CYP1A2 | |
| SCHEMBL2226168 | 1.00 | RORC (0.62) | RORCMC4RS1PR5S1PR1CYP1A2 | |
| SCHEMBL1976054 | 1.00 | RORC (0.62) | RORCMC4RS1PR5S1PR1CYP1A2 | |
| SCHEMBL8210627 | 1.00 | RORC (0.62) | RORCMC4RS1PR5S1PR1CYP1A2 | |
| SCHEMBL12303485 | 0.91 | RORC (0.64) | RORCS1PR5S1PR1 | |
| SCHEMBL1751711 | 0.91 | RORC (0.64) | RORCS1PR5S1PR1 | |
| SCHEMBL1752470 | 0.91 | RORC (0.64) | RORCS1PR5S1PR1 | |
| SCHEMBL1752417 | 0.91 | RORC (0.64) | RORCS1PR5S1PR1 | |
| SCHEMBL8484105 | 0.91 | RORC (0.64) | RORCS1PR5S1PR1 | |
| SCHEMBL419234 | 0.91 | RORC (0.64) | RORCS1PR5S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2398768-B1 | PYRROLIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2016-08-24 | — | — | EP | disclosed |
| US-8344161-B2 | Process for the preparation of pyrollidine-3-carboxylic acids | HOFFMANN-LA ROCHE INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-8344161-B2 | Process for the preparation of pyrollidine-3-carboxylic acids | HOFFMANN-LA ROCHE INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-8344161-B2 | Process for the preparation of pyrollidine-3-carboxylic acids | HOFFMANN-LA ROCHE INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-8318759-B2 | Pyrrolidine derivatives as NK3 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2012-11-27 | — | — | US | disclosed |
| EP-2398768-A1 | PYRROLIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2011-12-28 | — | — | EP | disclosed |
| WO-2010094667-A1 | PYRROLIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-08-26 | — | — | WO | disclosed |
| US-20100210659-A1 | PYRROLIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2010-08-19 | — | — | US | disclosed |
| WO-2010069793-A1 | PROCESS FOR THE PREPARATION OF PYROLLIDINE-3-CARBOXYLIC ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-06-24 | — | — | WO | disclosed |
| US-20100152462-A1 | PROCESS FOR THE PREPARATION OF PYROLLIDINE-3-CARBOXYLIC ACIDS | HOFFMANN-LA ROCHE, INC. | 2010-06-17 | — | — | US | disclosed |
| US-20100152462-A1 | PROCESS FOR THE PREPARATION OF PYROLLIDINE-3-CARBOXYLIC ACIDS | HOFFMANN-LA ROCHE, INC. | 2010-06-17 | — | — | US | disclosed |
| US-20100152462-A1 | PROCESS FOR THE PREPARATION OF PYROLLIDINE-3-CARBOXYLIC ACIDS | HOFFMANN-LA ROCHE, INC. | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210659-A1 | PYRROLIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | OPRL1, OPRK1, OPRD1 | RORC 1018/4885MC4R 109/4885S1PR5 708/4885 |
| US-20100152462-A1 | PROCESS FOR THE PREPARATION OF PYROLLIDINE-3-CARBOXYLIC ACIDS | PYCR1, PYGB, PCCA | RORC 722/4885MC4R 545/4885S1PR5 1881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.